ClinicalTrials.gg
CompletedNCT03814187ORION-8Updated Mar 6, 2024Results posted

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

A Phase 3 interventional study of Inclisiran Sodium in ASCVD, Elevated Cholesterol and Heterozygous Familial Hypercholesterolemia, sponsored by Novartis Pharmaceuticals. Completed at 238 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-06.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,275
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing inclisiran in Hypercholesterolemia — 6 open to participants now, 10 under way, 5 of them phase 3. inclisiran · Hypercholesterolemia.

Enrollment
4th of 24
3,275 · median 375
Started
2019
the only one that year
Phase 3
13 of 24
2 open now
Registered
5th of 24
by date
Lead sponsor
16 of 24
Novartis Pharmaceuticals

Among the 24 studies testing inclisiran in Hypercholesterolemia, this one is the 4th largest by enrollment, is the only one that started in 2019, is one of 13 in phase 3, and was the 5th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

6 of the 24 studies testing inclisiran in Hypercholesterolemia are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About inclisiran

inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing inclisiran in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this extension study was to evaluate the efficacy, safety, and tolerability of long-term dosing of Inclisiran. The study was a global multicenter study.

Read the detailed description

This study was an open label, long term extension study in subjects with atherosclerotic cardiovascular disease (ASCVD), ASCVD-risk equivalents (eg, diabetes and familial hypercholesterolemia), or heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL-C) despite maximum tolerated dose of LDL-C lowering therapies who have completed the inclisiran Phase II trial MDCO-PCS-16-01 (ORION-3; NCT03060577), or any of the following Phase III lipid lowering studies: MDCO-PCS-17-03 (ORION-9; NCT03397121), MDCO-PCS-17-04 (ORION-10; NCT03399370), or MDCO-PCS-17-08 (ORION-11; NCT03400800).

The End of Study (EOS) visit in the previous feeder studies was Day 1 in this extension study.The duration that each subject participated in this study was a maximum of 3 years. However, for subjects from the Study ORION-3, the Sponsor decided to end the study prior to completion of their full 3-year of participation. It is recorded in the database as discontinuation was due to Sponsor's decision.

In this Phase III extension study, the same study drug of inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) was administered as a single subcutaneous (SC) dose every 180 days from the last dose in previous feeder study (except for subjects newly initiating inclisiran, who received the first two doses 90 days apart) until the end of the study.

On Day 1 (EOS visit in the feeder study), subjects from the previous feeder studies received blinded study medication except subjects from Study ORION-3. Subjects who received placebo in the previous Phase III feeder study received blinded inclisiran and subjects who received inclisiran in the previous feeder study received blinded placebo at this visit, so that subjects previously on placebo received the correct dosing regime, i.e. a dose at Day 1, Day 90 and every 180-days thereafter. Subjects previously treated with inclisiran did not need a dose of inclisiran to maintain every 180-dosing regime and therefore, were given placebo in order to maintain the blinding of the feeder study. Subjects that moved over from ORION-3 received the first study medication at Day 90, as this study was already open-label.

On Day 90, all subjects received inclisiran sodium 300 mg. This is 180 days after the last injection in the previous feeder study for subjects that received inclisiran and was the second dose of inclisiran for the subjects that received placebo in the feeder study. The EOS visit occurred at Day 1080.

This extension study allowed subjects continued access to inclisiran treatment and allowed the collection of additional efficacy and safety data for long-term use beyond the end of the feeder studies.

03

Conditions studied

  • ASCVD
  • Elevated Cholesterol
  • Heterozygous Familial Hypercholesterolemia
  • Homozygous Familial Hypercholesterolemia

Keywords

  • Inclisiran sodium
  • ASCVD
  • LDL-C
  • HeFH
  • HoFH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Completion on a previously qualifying inclisiran Phase II trial MDCO-PCS-16-01 (ORION-3), or Phase III lipid lowering ORION feeder study [MDCO-PCS-17-03 (ORION-9), MDCO-PCS-17-4 (ORION-10), or MDCO-PCS-17-08 (ORION-11)] meaning the subject received the last dose of study drug and completed the final study visit per applicable protocol.
  2. On current lipid-lowering therapies (such as a statin and/or ezetimibe) from previous study with no planned medication or dose change during study participation.
  3. Willing and able to give before initiation of any study-related procedures and willing to comply with all required study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with participation in the clinical study, and/or put the subject at significant risk [according to investigator's (or delegate's) judgment] if he/she participates in the clinical study.
  2. An underlying known disease, or surgical, physical, or medical condition that, in the opinion of the investigator (or delegate) might interfere with interpretation of the clinical study results.
  3. Severe concomitant noncardiovascular disease that carries the risk of reducing to less than 3 years,
  4. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained (ALT), aspartate aminotransferase (AST), elevation >3x the (ULN), or total (TBIL) elevation >2x ULN at the last recorded visit in the feeder study prior to study entry visit.
  5. Females who are pregnant or nursing, or who are of and unwilling to use at least one method of acceptable effective (eg, oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, intrauterine device) for the entire duration of the study. Exemptions from this criterion:

    1. Women >2 years (defined as 1 year or longer since last menstrual period) and more than 55 years of age.
    2. Postmenopausal women (as defined above) and less than 55 years of age with a negative pregnancy test within 24 hours of randomization.
    3. Women who are surgically sterilized at least 3 months prior to enrollment.
  6. Planned use of other medicinal products other than inclisiran or devices during the course of the study.
  7. Any condition that according to the investigator could interfere with the conduct of the study, such as but not limited to:

    1. Subjects who are unable to communicate or to cooperate with the investigator
    2. Unable to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study (including subjects whose cooperation is doubtful due to drug abuse or alcohol dependency)
    3. Unlikely to comply with the protocol requirements, instructions, and study-related restrictions (eg, uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study)
    4. Have any medical or surgical condition, which in the opinion of the investigator would put the subject at increased risk from participating in the study
    5. Persons directly involved in the conduct of the study.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3,275 participants (actual)

Study arms

  • Experimental
    Inclisiran

    Inclisiran sodium 300 milligrams (mg) was administered as a single SC injection on Day 1\*, 90, then every 180 days to Day 990. \*Subjects who received blinded placebo in the feeder study received blinded inclisiran and subjects who received blinded inclisiran in the feeder study received blinded placebo on Day 1 in ORION-8. Subjects from the open label ORION-3 study did not receive any injection of study drug on Day 1. Their first dose of study medication was at day 90

    Drug: Inclisiran Sodium

Interventions

  • Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk

    The primary objective of the study is to evaluate the effect of inclisiran treatment on the proportion of subjects achieving prespecified LDL-C targets at end of study (EOS). Target is \<70 mg/dL for atherosclerotic cardiovascular disease (ASCVD) subjects and \<100 mg/dL for ASCVD risk equivalent subjects. Risk equivalent subjects are defined as either type 2 diabetes, familial hypercholesterolemia or a 10-year risk of a cardiovascular event ≥20% as assessed by the Framingham Risk Score or equivalent; without a medical history of coronary heart disease , cerebrovascular disease or peripheral artery disease.

    Time frame: From ORION-8 Day 1 to the end of study (up to 1080 days)

  2. Incidence of Treatment-emergent Adverse Events (TEAEs)

    Safety assessments include adverse events and serious adverse events until the end of study. End of study visit occured at least 90 days following the last inclisiran dose once a decision was made to end the study (either by the subject, investigator or sponsor). For subjects prematurely and permanently discontinued from study treatment, who were not willing to return within the 90 day timeframe, the EOS visit was scheduled as soon as possible, or if decision to discontinue and not return was made at a specific visit, this visit became the EOS visit.

    Time frame: From ORION-8 Day 1 to the end of study (up to 1080 days)

Secondary outcomes

  1. Absolute Change in LDL-C From the Initial Feeder Study Baseline

    Absolute change from baseline in low density lipoprotein cholesterol (LDL-C) was calculated to evaluate the effect of inclisiran on LDL-C levels.

    Time frame: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)

  2. Percentage Change in LDL-C From the Initial Feeder Study Baseline

    Percentage change from baseline in low density lipoprotein cholesterol (LDL-C) was calculated to evaluate the effect of inclisiran on LDL-C levels.

    Time frame: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)

  3. Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C

    Absolute change from baseline in total cholesterol, triglycerides and high density lipoprotein cholesterol (HDL-C) was calculated to evaluate the effect of inclisiran on other lipids and lipoproteins.

    Time frame: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)

  4. Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C

    Percentage change from baseline in total cholesterol (TC), triglycerides and high density lipoprotein cholesterol (HDL-C) was calculated to evaluate the effect of inclisiran on other lipids and lipoproteins.

    Time frame: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)

07

Results

Posted Mar 6, 2024

Participant flow

268 centers in 13 countries: United States(145), Canada(8), Czechia(4), Denmark(6), Germany(9), Hungary(4), Netherlands(12), Poland(18), South Africa(12), Spain(6), Sweden(3), Ukraine(8), United Kingdom(33)

Participant flow — Overall Study
MilestonePhase III Inclisiran-InclisiranPhase III Placebo-InclisiranORION-3 Rollover
Started15131478284
Safety population15121478284
Completed124612000
Not completed267278284
Withdrew: Sponsor's administrative decision00272
Withdrew: Death80814
Withdrew: Withdrew consent77782
Withdrew: Lost to follow-up47521
Withdrew: Adverse event22230
Withdrew: Physician decision742
Withdrew: Initiation of protocol-prohibited approved pcsk9 inhibitor001
Withdrew: Other reasons34402

Outcome measures

PrimaryProportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk

The primary objective of the study is to evaluate the effect of inclisiran treatment on the proportion of subjects achieving prespecified LDL-C targets at end of study (EOS). Target is \<70 mg/dL for atherosclerotic cardiovascular disease (ASCVD) subjects and \<100 mg/dL for ASCVD risk equivalent subjects. Risk equivalent subjects are defined as either type 2 diabetes, familial hypercholesterolemia or a 10-year risk of a cardiovascular event ≥20% as assessed by the Framingham Risk Score or equivalent; without a medical history of coronary heart disease , cerebrovascular disease or peripheral artery disease.

Time frame:
From ORION-8 Day 1 to the end of study (up to 1080 days)
Reported as:
Number · Percentage of participants
Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk
Percentage of participantsPhase III Inclisiran-InclisiranPhase III Placebo-InclisiranORION-3 RolloverTotal
% of subjects Who Attain Global Lipid Targets at Day 1080 / EOS78.18 (75.8 to 80.4)79.07 (76.7 to 81.3)76.81 (71.4 to 81.6)78.43 (76.8 to 80.0)
% of ASCVD subjects Who Attain Global Lipid Targets of <70 mg/dL at Day 1080 / EOS79.34 (76.8 to 81.7)79.96 (77.4 to 82.4)76.70 (70.0 to 82.5)79.41 (77.7 to 81.1)
% of ASCVD Risk Equivalent subjects Who Attain Global Lipid Targets of <100 mg/dL at Day 1080 / EOS72.56 (66.1 to 78.3)74.88 (68.6 to 80.5)77.00 (67.7 to 84.7)74.33 (70.4 to 78.0)
PrimaryIncidence of Treatment-emergent Adverse Events (TEAEs)

Safety assessments include adverse events and serious adverse events until the end of study. End of study visit occured at least 90 days following the last inclisiran dose once a decision was made to end the study (either by the subject, investigator or sponsor). For subjects prematurely and permanently discontinued from study treatment, who were not willing to return within the 90 day timeframe, the EOS visit was scheduled as soon as possible, or if decision to discontinue and not return was made at a specific visit, this visit became the EOS visit.

Time frame:
From ORION-8 Day 1 to the end of study (up to 1080 days)
Reported as:
Count of participants · Participants
Incidence of Treatment-emergent Adverse Events (TEAEs)
ParticipantsPhase III Inclisiran-InclisiranPhase III Placebo-InclisiranORION-3 RolloverTotal
Adverse events119711701812548
Adverse events :Treatment-related13314816297
SAEs46448243989
SAEs: Treatment-related2215
Fatal SAEs80814165
Fatal SAEs: Treatment-related0000
SecondaryAbsolute Change in LDL-C From the Initial Feeder Study Baseline

Absolute change from baseline in low density lipoprotein cholesterol (LDL-C) was calculated to evaluate the effect of inclisiran on LDL-C levels.

Time frame:
Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)
Reported as:
Mean · mg/dL
Absolute Change in LDL-C From the Initial Feeder Study Baseline
mg/dLPhase III Inclisiran-InclisiranPhase III Placebo-InclisiranORION-3 Rollover
ORION-8 Baseline-55.21 (-56.9 to -53.5)0.46 (-1.4 to 2.3)-61.58 (-66.4 to -56.8)
Day 1080 / EOS-55.81 (-58.0 to -53.6)-54.70 (-56.9 to -52.5)-64.31 (-69.0 to -59.7)
SecondaryPercentage Change in LDL-C From the Initial Feeder Study Baseline

Percentage change from baseline in low density lipoprotein cholesterol (LDL-C) was calculated to evaluate the effect of inclisiran on LDL-C levels.

Time frame:
Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)
Reported as:
Mean · Percentage change in LDL-C
Percentage Change in LDL-C From the Initial Feeder Study Baseline
Percentage change in LDL-CPhase III Inclisiran-InclisiranPhase III Placebo-InclisiranORION-3 Rollover
ORION-8 Baseline-50.02 (-51.3 to -48.8)3.10 (1.4 to 4.9)-48.22 (-51.2 to -45.2)
Day 1080 / EOS-48.96 (-50.5 to -47.4)-49.69 (-51.3 to -48.0)-49.95 (-52.6 to -47.3)
SecondaryAbsolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C

Absolute change from baseline in total cholesterol, triglycerides and high density lipoprotein cholesterol (HDL-C) was calculated to evaluate the effect of inclisiran on other lipids and lipoproteins.

Time frame:
Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)
Reported as:
Mean · mg/dL
Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C
mg/dLPhase III Inclisiran-InclisiranPhase III Placebo-InclisiranORION-3 Rollover
ORION-8 Baseline Total Cholesterol (TC)-59.05 (-61.0 to -57.1)-0.07 (-2.2 to 2.1)-63.11 (-68.3 to -57.9)
Day 1080 / EOS Total Cholesterol (TC)-58.48 (-61.0 to -55.9)-57.08 (-59.6 to -54.6)-65.43 (-70.5 to -60.3)
ORION-8 Baseline Triglycerides-21.50 (-25.1 to -17.9)-5.74 (-9.5 to -2.0)-14.43 (-23.7 to -5.1)
Day 1080 / EOS Triglycerides-19.58 (-23.7 to -15.4)-22.12 (-26.3 to -17.9)-21.32 (-30.3 to -12.4)
ORION-8 Baseline HDL Cholesterol3.37 (2.9 to 3.9)0.59 (0.1 to 1.1)3.41 (2.2 to 4.6)
Day 1080 / EOS HDL Cholesterol3.60 (3.0 to 4.2)4.39 (3.8 to 5.0)5.27 (3.8 to 6.7)
SecondaryPercentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C

Percentage change from baseline in total cholesterol (TC), triglycerides and high density lipoprotein cholesterol (HDL-C) was calculated to evaluate the effect of inclisiran on other lipids and lipoproteins.

Time frame:
Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)
Reported as:
Mean · Percentage change
Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C
Percentage changePhase III Inclisiran-InclisiranPhase III Placebo-InclisiranORION-3 Rollover
ORION-8 Baseline Total Cholesterol (TC)-30.64 (-31.5 to -29.7)1.28 (0.1 to 2.4)-29.49 (-31.6 to -27.4)
Day 1080 / EOS Total Cholesterol (TC)-29.34 (-30.5 to -28.2)-29.53 (-30.7 to -28.4)-30.44 (-32.4 to -28.5)
ORION-8 Baseline Triglycerides-7.84 (-10.0 to -5.7)3.03 (0.8 to 5.2)-0.20 (-7.6 to 7.2)
Day 1080 / EOS Triglycerides-3.90 (-6.5 to -1.3)-6.85 (-9.2 to -4.5)-3.18 (-9.2 to 2.8)
ORION-8 Baseline HDL Cholesterol9.28 (8.2 to 10.4)3.48 (2.4 to 4.6)8.13 (5.7 to 10.5)
Day 1080 / EOS HDL Cholesterol9.91 (8.7 to 11.2)11.75 (10.3 to 13.2)12.16 (9.3 to 15.0)

Adverse events

Collected over Adverse events were reported from the start of study in ORION-8 until end of study treatment plus 90 days post treatment, up to a maximum duration of 1080 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase III Inclisiran-Inclisiran80/1,512 (5.3%)464/1,512 (30.7%)1,110/1,512 (73.4%)
Phase III Placebo-Inclisiran81/1,478 (5.5%)482/1,478 (32.6%)1,073/1,478 (72.6%)
ORION-3 Rollover4/284 (1.4%)43/284 (15.1%)169/284 (59.5%)
Total165/3,274 (5%)989/3,274 (30.2%)2,352/3,274 (71.8%)
Most frequent serious events
Showing 10 of 559
Most frequent serious events
EventPhase III Inclisiran-InclisiranPhase III Placebo-InclisiranORION-3 RolloverTotal
Coronary artery diseaseCardiac disorders36/151226/14782/28464/3274
COVID-19Infections and infestations21/151228/14780/28449/3274
Acute myocardial infarctionCardiac disorders17/151224/14783/28444/3274
COVID-19 pneumoniaInfections and infestations14/151221/14780/28435/3274
Angina pectorisCardiac disorders21/151220/14782/28443/3274
OsteoarthritisMusculoskeletal and connective tissue disorders16/151220/14780/28436/3274
Myocardial infarctionCardiac disorders12/151219/14782/28433/3274
DeathGeneral disorders12/151219/14782/28433/3274
Angina unstableCardiac disorders12/151218/14782/28432/3274
PneumoniaInfections and infestations16/151217/14782/28435/3274
Most frequent other events
Showing 10 of 1,410
Most frequent other events
EventPhase III Inclisiran-InclisiranPhase III Placebo-InclisiranORION-3 RolloverTotal
COVID-19Infections and infestations178/1512176/147852/284406/3274
Diabetes mellitus inadequate controlMetabolism and nutrition disorders114/1512109/14783/284226/3274
HypertensionVascular disorders106/1512110/14789/284225/3274
ArthralgiaMusculoskeletal and connective tissue disorders94/1512102/14785/284201/3274
Diabetes mellitusMetabolism and nutrition disorders98/1512100/14787/284205/3274
Urinary tract infectionInfections and infestations77/151260/147810/284147/3274
Back painMusculoskeletal and connective tissue disorders67/151251/14788/284126/3274
NasopharyngitisInfections and infestations61/151244/14785/284110/3274
OsteoarthritisMusculoskeletal and connective tissue disorders60/151253/14786/284119/3274
Upper respiratory tract infectionInfections and infestations56/151250/14784/284110/3274

Baseline characteristics

Demographic and baseline characteristics are based on the safety population, as primary and secondary analysis are based on the safety population. The safety population consisted of all ORION-3 rollover subjects who signed the informed consent to Study ORION-8, and all ORION-9/ORION-10/ORION-11 rollover subjects with at least one study drug administration in Study ORION-8

Age, Continuous
Age, Continuous(years)Phase III Inclisiran-InclisiranPhase III Placebo-InclisiranORION-3 RolloverTotal
Mean64.7 ± 9.8364.6 ± 9.8267.7 ± 9.9764.9 ± 9.88
Sex: Female, Male
Sex: Female, Male(Participants)Phase III Inclisiran-InclisiranPhase III Placebo-InclisiranORION-3 RolloverTotal
Female4824761001058
Male103010021842216
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase III Inclisiran-InclisiranPhase III Placebo-InclisiranORION-3 RolloverTotal
American Indian/Alaska Native3227
Asian177327
Black/African American103787188
Native Hawaiian/Other Pacific Islander64010
White138313872713041
Missing0011
08

Study locations

238 sites
  • Research Site 10001-015
    Birmingham, Alabama 35211, United States
  • Research Site 10001-138
    Foley, Alabama 36535, United States
  • Research Site 10001-113
    Huntsville, Alabama 35801, United States
  • Research Site 10001-058
    Mobile, Alabama 36608, United States
  • Research Site 10001-037
    Montgomery, Alabama 36117, United States
  • Research Site 10001-076
    Saraland, Alabama 36571, United States
  • Research Site 10001-013
    Chandler, Arizona 85224, United States
  • Research Site 10001-077
    Mesa, Arizona 85213, United States
  • Research Site 10001-136
    Phoenix, Arizona 85014, United States
  • Research Site 10001-051
    Surprise, Arizona 85374, United States
  • Research Site 10001-019
    Tucson, Arizona 85712, United States
  • Research Site 10001-004
    Tucson, Arizona 85741, United States
  • Research Site 10001-132
    Tucson, Arizona 85745, United States
  • Research Site 10001-073
    Beverly Hills, California 90211, United States
  • Research Site 10001-050
    Canoga Park, California 91303, United States
  • Research Site 10001-011
    Carlsbad, California 92008, United States
  • Research Site 10001-065
    El Cajon, California 92020, United States
  • Research Site 10001-150
    Los Angeles, California 90022, United States
  • Research Site 90001-005
    Mission Viejo, California 92691, United States
  • Research Site 10001-043
    Northridge, California 91324, United States
  • Research Site 10001-022
    Northridge, California 91325, United States
  • Research Site 10001-033
    Sacramento, California 95821-2134, United States
  • Research Site 10001-105
    San Ramon, California 94582, United States
  • Research Site 10001-008
    Santa Rosa, California 95405, United States
  • Research Site 10001-153
    Spring Valley, California 91978, United States
  • Research Site 90001-015
    Stanford, California 94305, United States
  • Research Site 10001-044
    Torrance, California 90502, United States
  • Research Site 90001-047
    Boca Raton, Florida 33434, United States
  • Research Site 10001-084
    Clearwater, Florida 33756, United States
  • Research Site 10001-155
    Clearwater, Florida 33756, United States
  • Research Site 10001-099
    Clearwater, Florida 33761, United States
  • Research Site 10001-127
    Daytona Beach, Florida 32117, United States
  • Research Site 10001-119
    Fleming Island, Florida 32003, United States
  • Research Site 10001-070
    Fort Lauderdale, Florida 33308, United States
  • Research Site 10001-067
    Hialeah, Florida 33012, United States
  • Research Site 10001-139
    Jacksonville, Florida 32204, United States
  • Research Site 10001-039
    Jacksonville, Florida 32216, United States
  • Research Site 10001-098
    Jacksonville, Florida 32216, United States
  • Research Site 10001-080
    Miami Springs, Florida 33166, United States
  • Research Site 10001-081
    Miami, Florida 33126, United States
  • Research Site 10001-140
    Miami, Florida 33126, United States
  • Research Site 10001-142
    Miami, Florida 33126, United States
  • Research Site 10001-030
    Miami, Florida 33165, United States
  • Research Site 10001-116
    Miami, Florida 33183, United States
  • Research Site 10001-027
    Pembroke Pines, Florida 33024, United States
  • Research Site 10001-115
    Pembroke Pines, Florida 33027, United States
  • Research Site 10001-048
    Pembroke Pines, Florida 33029, United States
  • Research Site 10001-147
    Pembroke Pines, Florida 33029, United States
  • Research Site 10001-003
    Pinellas Park, Florida 33781, United States
  • Research Site 10001-104
    Ponte Vedra, Florida 32081, United States
  • Research Site 10001-090
    Saint Augustine, Florida 32086, United States
  • Research Site 10001-102
    Saint Petersburg, Florida 33713, United States
  • Research Site 10001-123
    Sarasota, Florida 34239-3513, United States
  • Research Site 10001-143
    Tampa, Florida 33614, United States
  • Research Site 10001-069
    Atlanta, Georgia 30342, United States
  • Research Site 10001-137
    Dunwoody, Georgia 30338, United States
  • Research Site 10001-092
    Macon, Georgia 31210, United States
  • Research Site 10001-059
    Arlington Heights, Illinois 60005, United States
  • Research Site 10001-158
    Chicago, Illinois 60652, United States
  • Research Site 10001-036
    Evanston, Illinois 60201, United States
  • Research Site 10001-082
    Indianapolis, Indiana 46260, United States
  • Research Site 10001-040
    Valparaiso, Indiana 46383, United States
  • Research Site 10001-074
    West Des Moines, Iowa 50266, United States
  • Research Site 10001-028
    Hutchinson, Kansas 67502, United States
  • Research Site 10001-125
    Lexington, Kentucky 40503, United States
  • Research Site 10001-108
    Lexington, Kentucky 40504, United States
  • Research Site 10001-107
    Owensboro, Kentucky 42303, United States
  • Research Site 10001-144
    Crowley, Louisiana 70526, United States
  • Research Site 10001-041
    Lake Charles, Louisiana 70601, United States
  • Research Site 10001-101
    Monroe, Louisiana 71201, United States
  • Research Site 90001-004
    Boston, Massachusetts 02114, United States
  • Research Site 10001-024
    Flint, Michigan 48504, United States
  • Research Site 10001-095
    Grandville, Michigan 49418, United States
  • Research Site 10001-078
    Sterling Heights, Michigan 48310, United States
  • Research Site 10001-034
    Troy, Michigan 48098, United States
  • Research Site 10001-018
    Edina, Minnesota 55435, United States
  • Research Site 90001-056
    Saint Paul, Minnesota 55102, United States
  • Research Site 10001-156
    Saint Louis, Missouri 63136, United States
  • Research Site 10001-007
    Saint Louis, Missouri 63141, United States
  • Research Site 90001-012
    Butte, Montana 59701, United States
  • Research Site 10001-053
    Omaha, Nebraska 68134, United States
  • Research Site 10001-021
    Omaha, Nebraska 68144, United States
  • Research Site 90001-112
    Las Vegas, Nevada 89119, United States
  • Research Site 10001-124
    Las Vegas, Nevada 89121, United States
  • Research Site 10001-060
    Bridgewater, New Jersey 08807, United States
  • Research Site 90001-014
    Summit, New Jersey 07901, United States
  • Research Site 10001-055
    Warren, New Jersey 07059, United States
  • Research Site 10001-054
    Albany, New York 12206, United States
  • Research Site 10001-122
    Binghamton, New York 13901, United States
  • Research Site 10001-128
    Endwell, New York 13760, United States
  • Research Site 10001-042
    New Windsor, New York 12553, United States
  • Research Site 10001-129
    Poughkeepsie, New York 12601, United States
  • Research Site 10001-110
    Williamsville, New York 14221, United States
  • Research Site 10001-063
    Cary, North Carolina 27518, United States
  • Research Site 10001-064
    Greensboro, North Carolina 27401, United States
  • Research Site 10001-145
    Mooresville, North Carolina 28117, United States
  • Research Site 10001-046
    Shelby, North Carolina 28150, United States
  • Research Site 10001-016
    Akron, Ohio 443311, United States
  • Research Site 10001-120
    Cincinnati, Ohio 45219, United States
  • Research Site 90001-002
    Cincinnati, Ohio 45227, United States

Showing the first 100 of 238 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Warden BA, Duell PB. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins. J Cardiovasc Pharmacol. 2021 Aug 1;78(2):e157-e174. doi: 10.1097/FJC.0000000000001053. PubMed 33990512 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Feb 2023, 45 months.

Results were first posted in Mar 2024, 1 year after primary completion.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 45 months is above that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2019
First posted
Jan 23, 2019
StartActual
Apr 16, 2019
Primary completionActual
Feb 13, 2023
CompletionActual
Feb 13, 2023
Results first posted
Mar 6, 2024
Last update
Mar 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03814187
Responsible party
Sponsor
First posted
Jan 23, 2019
Start date
Apr 16, 2019
Primary completion
Feb 13, 2023
Completion
Feb 13, 2023
Results posted
Mar 6, 2024
Last update
Mar 6, 2024

Study contacts

Scott Wright, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion